Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces
Massachusetts Eye and Ear Infirmary · with Boston Children's Hospital, University of Washington · NCT05867173
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 4 mo+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 200
- US sites recruiting
- 2
- Study start
- September 16, 2022
- Record last updated
- November 26, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Despite the success of cochlear implants, devices surgically placed in the inner ears of patients with severe hearing loss, there remains substantial variability in the overall speech perception outcomes for the children and adults who receive them. The main goals of this project are: i) to improve our understanding of how cochlear implants affect the developing auditory system, ii) apply that knowledge to test new methods for programming children and adults, and iii) to study how long it takes listeners to adapt to new cochlear implant programs over the short- and long-term. The results will improve our understanding of how the deafened auditory system develops with cochlear implant stimulation and advance clinical practice to improve hearing outcomes in cochlear implant listeners.
Being studied: Experimental Speech Processing Strategy
Conditions: Deafness
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Research Subjects with a Cochlear Implant ADULTS Inclusion Criteria
- Adult at least 18 years old
- Native speakers of American English
- Wears a cochlear implant manufactured by Advanced Bionics (Clarion Hi-Focus I or newer), Cochlear, or MED-EL
CHILDREN Inclusion Criteria
- Children at least 3 months old
- Native speakers of American English
- Wears a cochlear implant manufactured by Advanced Bionics (Clarion Hi-Focus I or newer), Cochlear, or MED-EL
- For both children and adults with a cochlear implant, some study criteria might pertain to a subset of subjects, such as a specific age at which the subjects developed a hearing loss, or was implanted.
Exclusion Criteria
Exclusion for all Cochlear Implant Subjects:
- Inability to provide informed consent
- Does not meet the inclusion criteria for a specific study protocol, such as age of onset of hearing loss, age of cochlear implantation, duration of deafness, number of active electrodes in the cochlear implant device
- Unable to carry out the study protocol or tasks required in the study
Exclusion for all Normal Hearing Subjects
- Inability to provide informed consent
- Hearing loss, or significant history of hearing related issues
- Unable to carry out the study protocol or tasks required in the study
Recruiting US locations
Mass Eye and Ear
Boston, MA 02114
Site contact: Julie Arenberg · 617-807-7904 · julie_arenberg@meei.harvard.edu
Boston Children's Hospital
Waltham, MA 02453
Site contact: Amanda Griffin · 781-216-3657 · amanda.griffin@childrens.harvard.edu
Study contacts (from the official record)
- Julie Arenberg · 617-807-7904 · julie_arenberg@meei.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+